Rational design and evaluation of HBsAg polymeric nanoparticles as antigen delivery carriers

Dewangan, Hitesh Kumar; Pandey, Tarun; Maurya, Lakshmi; Singh, Sanjay

doi:10.1016/j.ijbiomac.2018.01.073

Cited by 54 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This formation of smaller droplets may be due to the higher amount of stabilizer present as compared to the non-sufficient amount of stabilizer when using a lower amount of this phase. It was also recently reported that increasing the continuous phase volume:organic phase ratio had led to particle size reduction (27).…”

Section: Resultsmentioning

confidence: 94%

“…The positive effect that the PLGA amount has on EE (Fig. 4) could be again due to the fact of increasing the viscosity of the organic phase with a higher amount of polymer, which can retard drug diffusion into the external aqueous phase and thus increase the amount of drug entrapped inside the NPs (27,28). It is also known that larger nanoparticles obtained with a higher PLGA level can provide sufficient surface for entrapping the peptide drug.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery

et al. 2019

View full text Add to dashboard Cite

Purpose To design and stabilize Liraglutide loaded poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) proper for oral administration. Methods PLGA NPs were prepared by means of double emulsion solvent evaporation method and optimized by applying 7-factor 2-level Plackett-Burman screening design. Results Spherical shaped NPs with homogeneous distribution, 188.95 nm particle size and 51.81% encapsulation efficiency were obtained. Liraglutide was successfully entrapped in the NPs while maintaining its native amorphous nature, and its structural integrity as well. Conclusion Lira-PLGA NPs with the required Critical Quality Attributes (CQAs) were successfully designed by implementing a 7-factor 8-run Plackett Burman design into the extended Quality by Design (QbD) model, to elucidate the effect of formulation and process variables on the particle size, size-distribution, encapsulation efficiency and surface charge. As the developed nanoparticles maintained the native structure of the active pharmaceutical ingredient (API), they are promising compositions for the further development for the oral delivery of Lira. Graphical Abstract Electronic supplementary material The online version of this article (10.1007/s11095-019-2620-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There have been many studies of PLGA particles application for the delivery of vaccines to induce efficient immunity in various diseases such as hepatitis B, tuberculosis, chlamydia, leishmaniasis, toxoplasmosis, and malaria (Allahyari and Mohit 2016). The PLGA particles could achieve a long-lasting effect in different disease models; hence, the need for multiple injections associated with conventional vaccines can be avoided (Dewangan et al 2018;Saini et al 2011). In a study by Feng et al, a single subcutaneous injection of PLGA MPs loaded with recombinant hepatitis B surface antigen (HBsAg) in mice resulted in antibody responses comparable to those of three injections of the conventional HBsAg vaccine (Feng et al 2006).…”

Section: Vaccine Deliverymentioning

confidence: 99%

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Emami

Yazdi

2019

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Pulmonary route is an attractive target for both systemic and local drug delivery, with the advantages of a large surface area, rich blood supply, and absence of first-pass metabolism. Numerous polymeric micro/nanoparticles have been designed and studied for controlled and targeted drug delivery to the lung. Area covered Among the natural and synthetic polymers for polymeric particles, poly(lactic acid) (PLA) and poly(lacticco-glycolic acid) (PLGA) have been widely used for the delivery of anti-cancer agents, anti-inflammatory drugs, vaccines, peptides, and proteins because of their highly biocompatible and biodegradable properties. This review focuses on the characteristics of PLA/PLGA particles as carriers of drugs for efficient delivery to the lung. Furthermore, the manufacturing techniques of the polymeric particles, and their applications for inhalation therapy were discussed. Expert opinion Compared to other carriers including liposomes, PLA/PLGA particles present a high structural integrity providing enhanced stability, higher drug loading, and prolonged drug release. Adequately designed and engineered polymeric particles can contribute to a desirable pulmonary drug delivery characterized by a sustained drug release, prolonged drug action, reduction in the therapeutic dose, and improved patient compliance.

show abstract

“…Thomas et al [330] have created porous PLGA, as well as PLA NPs loaded with a specific antigen (i.e., HBsAg) that induced enhanced immune responses. Dewangan et al [331] have also designed an HBsAg PLGA-loaded nanovaccine that demonstrated sustained release and better internalization in macrophage and MRC-5 cell lines. The researchers have tested several single-dose administration routes, obtaining the best results, in terms of immune-stimulating activity, for the intramuscular route; particularly, the nanovaccine administered in this way produced better humoral and cellular responses.…”

Section: Immunomodulationmentioning

confidence: 99%

Polymer-Based Nanosystems—A Versatile Delivery Approach

Niculescu

Grumezescu

2021

Materials

View full text Add to dashboard Cite

Polymer-based nanoparticles of tailored size, morphology, and surface properties have attracted increasing attention as carriers for drugs, biomolecules, and genes. By protecting the payload from degradation and maintaining sustained and controlled release of the drug, polymeric nanoparticles can reduce drug clearance, increase their cargo’s stability and solubility, prolong its half-life, and ensure optimal concentration at the target site. The inherent immunomodulatory properties of specific polymer nanoparticles, coupled with their drug encapsulation ability, have raised particular interest in vaccine delivery. This paper aims to review current and emerging drug delivery applications of both branched and linear, natural, and synthetic polymer nanostructures, focusing on their role in vaccine development.

show abstract

Rational design and evaluation of HBsAg polymeric nanoparticles as antigen delivery carriers

Cited by 54 publications

References 39 publications

Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery

Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery

Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery

Polymer-Based Nanosystems—A Versatile Delivery Approach

Contact Info

Product

Resources

About